Crinò L, et al. - In an expanded access program (EAP) in Italy with 1,588 patients with non-squamous non-small-cell lung cancer (NSCLC), with 409 having asymptomatic or controlled brain metastases, researchers assessed the effectiveness as well as safety of nivolumab. The participants had non-squamous NSCLC in progression after at least one systemic treatment for stage IIIB/IV disease and were given nivolumab 3 mg/kg intravenously every 2 weeks. Only participants who were asymptomatic, neurologically stable and either off corticosteroids or on a stable or decreasing dose of ≤ 10 mg/day prednisone were allowed to be included if they had brain metastases. A complete response was seen in four patients, 64 had a partial response and 96 showed stable disease. The median overall survival was 8.6 months. Findings corroborated the activity of nivolumab in non-squamous NSCLC patients with brain metastases, even with poor prognosis. Also, its safety profile was consistent with results in the EAP overall population and in patients with other malignancies.